Company / Current Assets
Fulcrum Therapeutics, Inc. Current Assets History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$357.5M
FY2025
5-year range
$207.5M / $357.5M
FY2021-FY2025
Trend
+43.0%
vs FY2024
Sector context
#143 of 213
Health Care
What the data says
At $357M, Fulcrum Therapeutics, Inc.'s current assets ranks #143 of 213 in the Health Care sector. Current Assets has increased for 3 consecutive years, from $208M in FY2022 to $357M in FY2025.
Based on SEC 10-K filings.
$357M in FY2025 with a 5-year CAGR of +24.5%.
Improved from $242M to $357M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +19.9%
- 5-Year CAGR
- +24.5%
- 10-Year CAGR
- -
Sector benchmark
#143 of 213 in Health CareTop 67% of 213This company $357.5M Sector average $2.5B
▼
-85.8% below sector average
Key checks
Key Insights
- Fulcrum Therapeutics, Inc.'s current assets has grown for 3 consecutive years.
- 5-year CAGR of +24.5%, indicating consistent growth.
- In FY2025, current assets increased 43.0% year-over-year.
- Ranks #143 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $357.5M | +43.0% |
| FY2024 | $249.9M | +3.2% |
| FY2023 | $242.2M | +16.7% |
| FY2022 | $207.5M | -8.2% |
| FY2021 | $226.0M | +89.1% |
| FY2020 | $119.5M | +19.4% |
| FY2019 | $100.1M | +35.1% |
| FY2018 | $74.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026